Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Eli Lilly And Co (LLY) Price & Performance

EPR PropertiesTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Eli Lilly And Co — how do they compare? EPR Properties trades at $61.55 (market cap $4.60B), while Eli Lilly And Co trades at $1,171 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 223.9× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.19%). Which is the better fit depends on your goals.

EPRLLY
Market Cap
$4.60B$1.03T
Sector
Real EstateHealth
52-Week High
$60.81$1.24K
52-Week Low
$48.71$625.65
Enterprise Value
$7.66B$1.07T
Dividend Yield
6.19%0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties (EPR) trades at $61.80, up 3.8% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $63.25. The REIT maintains strong profitability with a 39.93% net income margin and 10.68% ROE, supported by recent earnings beats and a strategic shift toward experiential assets like the $315 million Six Flags acquisition. Monthly dividends of $0.31 provide a steady income stream, with Q2 2026 earnings results due July 29, 2026.

Outlook remains positive due to high occupancy, dividend yield, and portfolio diversification, but risks include reliance on consumer spending and potential interest rate impacts. Analyst sentiment is mixed with a hold-heavy consensus, suggesting cautious optimism for income-focused investors amid stable fundamentals.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY